Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma

Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approxim...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Exp Clin Cancer Res
Päätekijät: Liu, Ziyu, Lin, Yan, Zhang, Jinyan, Zhang, Yumei, Li, Yongqiang, Liu, Zhihui, Li, Qian, Luo, Ming, Liang, Rong, Ye, Jiazhou
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827249/
https://ncbi.nlm.nih.gov/pubmed/31684985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1412-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia